Efficacy of XXXX in anxious-depressed @entity1 : results of a controlled multicenter trial versus @entity3659 .

@entity1 @entity14256 @entity3659 @entity13707 @entity148 @entity39004
265 adult outpatients with @entity14256 (DSM-III) associated with clinically manifest @entity148 (according to FDA criteria) were included in a multicenter, randomized double-blind study. The trial consisted of three phases: placebo pretreatment phase and inclusion in the trial, treatment phase, placebo posttreatment phase. @entity1 were treated in monotherapy for 42 days with a mean dosage of 3 tablets per day corresponding to 37.5 mg/day of @entity13707 or 75 mg/day of @entity3659 respectively. The following assessment instruments were used: the Montgomery and Asberg Depression Rating Scale (MADRS), the @entity148 ( @entity148 ), and the Check-List for the Evaluation of Somatic Symptoms of J.D. Guelfi and C.B. Pull (CHESS 82). Analysis of MADRS total scores showed an important and rapid improvement in @entity13707 and @entity3659 groups, reaching statistical significance as soon as D7. At the end of the 6-week treatment period the @entity13707 group reached a decrease of 64% in the initial MADRS total score versus 69% in the @entity3659 group. 78% of @entity1 treated with @entity13707 and 83% of @entity1 treated with @entity3659 were considered as treatment responders. There was no difference in drop-out rates between the two groups. @entity148 scores showed a decrease in psychic as well as somatic @entity148 in both groups. The action of @entity13707 on anxious-depressive symptomatology was confirmed by the concomitant improvement of global clinical rating and @entity1 ' self-rating ( @entity39004 ). Statistical comparison of all clinical rating-scale scores in @entity1 having completed the trial failed to show any significant group differences.(ABSTRACT TRUNCATED AT 250 WORDS)
